Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

368 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Fludarabine plus reduced-intensity busulfan versus fludarabine plus myeloablative busulfan in patients with non-Hodgkin lymphoma undergoing allogeneic hematopoietic cell transplantation.
Kamijo K, Shimomura Y, Shinohara A, Mizuno S, Kanaya M, Usui Y, Kim SW, Ara T, Mizuno I, Kuriyama T, Nakazawa H, Matsuoka KI, Kusumoto S, Maseki N, Yamaguchi M, Ashida T, Onizuka M, Fukuda T, Atsuta Y, Kondo E. Kamijo K, et al. Among authors: ashida t. Ann Hematol. 2023 Mar;102(3):651-661. doi: 10.1007/s00277-023-05084-x. Epub 2023 Jan 12. Ann Hematol. 2023. PMID: 36631705 Free PMC article.
Upfront allogeneic hematopoietic cell transplantation (HCT) versus remission induction chemotherapy followed by allogeneic HCT for acute myeloid leukemia with multilineage dysplasia: A propensity score matched analysis.
Konuma T, Harada K, Yamasaki S, Mizuno S, Uchida N, Takahashi S, Onizuka M, Nakamae H, Hidaka M, Fukuda T, Ohashi K, Kohno A, Matsushita A, Kanamori H, Ashida T, Kanda J, Atsuta Y, Yano S; Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation. Konuma T, et al. Among authors: ashida t. Am J Hematol. 2019 Jan;94(1):103-110. doi: 10.1002/ajh.25336. Epub 2018 Nov 29. Am J Hematol. 2019. PMID: 30370944 Free article.
Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Myelodysplastic/Myeloproliferative Neoplasms-Unclassifiable: A Retrospective Nationwide Study of the Japan Society for Hematopoietic Cell Transplantation.
Kurosawa S, Shimomura Y, Tachibana T, Ishiyama K, Ota S, Kobayashi T, Uchida N, Fukushima K, Ashida T, Matsuoka KI, Kanda J, Ichinohe T, Atsuta Y, Murata M, Aoki J. Kurosawa S, et al. Among authors: ashida t. Biol Blood Marrow Transplant. 2020 Sep;26(9):1607-1611. doi: 10.1016/j.bbmt.2020.05.013. Epub 2020 May 23. Biol Blood Marrow Transplant. 2020. PMID: 32454216 Free article.
Minimal residual disease (MRD) positivity at allogeneic hematopoietic cell transplantation, not the quantity of MRD, is a risk factor for relapse of Philadelphia chromosome-positive acute lymphoblastic leukemia.
Akahoshi Y, Arai Y, Nishiwaki S, Mizuta S, Marumo A, Uchida N, Kanda Y, Sakai H, Takada S, Fukuda T, Fujisawa S, Ashida T, Tanaka J, Atsuta Y, Kako S. Akahoshi Y, et al. Among authors: ashida t. Int J Hematol. 2021 Jun;113(6):832-839. doi: 10.1007/s12185-021-03094-x. Epub 2021 Feb 11. Int J Hematol. 2021. PMID: 33570732 Clinical Trial.
Adding melphalan to fludarabine and a myeloablative dose of busulfan improved survival after allogeneic hematopoietic stem cell transplantation in a propensity score-matched cohort of hematological malignancies.
Shimomura Y, Hara M, Yamamoto H, Uchida N, Kawakita T, Ashida T, Takada S, Ikeda T, Morishige S, Maruyama Y, Wake A, Ichinohe T, Fukuda T, Takanashi M, Atsuta Y, Ishikawa T. Shimomura Y, et al. Among authors: ashida t. Bone Marrow Transplant. 2021 Jul;56(7):1691-1699. doi: 10.1038/s41409-021-01217-w. Epub 2021 Mar 3. Bone Marrow Transplant. 2021. PMID: 33658646
Advantages of peripheral blood stem cells from unrelated donors versus bone marrow transplants in outcomes of adult acute myeloid leukemia patients.
Jo T, Arai Y, Kondo T, Mizuno S, Hirabayashi S, Inamoto Y, Doki N, Fukuda T, Ozawa Y, Katayama Y, Kanda Y, Fukushima K, Matsuoka KI, Takada S, Sawa M, Ashida T, Onizuka M, Ichinohe T, Atsuta Y, Kanda J, Yanada M. Jo T, et al. Among authors: ashida t. Cytotherapy. 2022 Oct;24(10):1013-1025. doi: 10.1016/j.jcyt.2022.05.009. Epub 2022 Jun 18. Cytotherapy. 2022. PMID: 35729020 Free article.
Short-term clinical outcomes after HLA 1-locus mismatched uPBSCT are similar to that after HLA-matched uPBSCT and uBMT.
Fuji S, Miyamura K, Kanda Y, Fukuda T, Kobayashi T, Ozawa Y, Iwato K, Uchida N, Eto T, Ashida T, Mori T, Sawa M, Ichinohe T, Atsuta Y, Kanda J; HLA Working Group of the Japan Society for Hematopoietic Cell Transplantation. Fuji S, et al. Among authors: ashida t. Int J Hematol. 2019 Jun;109(6):684-693. doi: 10.1007/s12185-019-02631-z. Epub 2019 Mar 15. Int J Hematol. 2019. PMID: 30877606
368 results